Tocilizumab for severe refractory neuro-Behçet: Three cases IL-6 blockade in neuro-Behçet

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 4, 2015, Pages 472-475

  Addimanda, Olga ^a   Pipitone, Nicolò ^a   Pazzola, Giulia ^a   Salvarani, Carlo ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Anti TNF alfa agents; Biologic therapies; Corticosteroids; IL 6; IL 6 blockade; Neuro Beh et; Refractory disease

Indexed keywords

ALPHA2A INTERFERON; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 6; PREDNISONE; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BEHCET DISEASE; BLOODY DIARRHEA; CASE REPORT; CAUCASIAN; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; COLOR ULTRASOUND FLOWMETRY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; EVOKED VISUAL RESPONSE; FEMALE; FEVER; GAIT DISORDER; HEADACHE; HUMAN; LIMB WEAKNESS; MIDDLE AGED; MUSCLE WEAKNESS; NEURO BEHCET DISEASE; NEUROGENIC BLADDER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OPHTHALMOSCOPY; OPTIC NEURITIS; PAIN; PARESTHESIA; PRIORITY JOURNAL; PTOSIS; TREATMENT DURATION; TREATMENT RESPONSE; URINE INCONTINENCE; VISUAL ACUITY; VISUAL IMPAIRMENT; WALKING DIFFICULTY; ANTAGONISTS AND INHIBITORS; BEHCET SYNDROME; BRAIN; DRUG COMBINATION; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BEHCET SYNDROME; BRAIN; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-6; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84927605289     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.08.004     Document Type: Article

References (30)

1. Siva A., Altintas A., Saip S. Behcet's syndrome and the nervous system. Curr Opin Neurol 2004, 17:347-357.
2. Pipitone N., Boiardi L., Olivieri I., Cantini F., Salvi F., Malatesta R., et al. Clinical manifestations of Behcet[U+05F3]s disease in 137 Italian patients: results of a multicenter study. Clin Exp Rheumatol 2004, 22(6 Suppl. 36):S46-S51.
3. Gurler A., Boyvat A., Tursen U. Clinical manifestations of Behçet's Disease: an analysis of 2147 patients. Yonsei Med J 1997, 38:423-427.
4. al-Dalaan A.N., al-Balaa S.R., el Ramahi K., et al. Behçet's Disease in Saudi Arabia. J Rheumatol 1994, 21:658-661.
5. Akman-Demir G., Serdaroglu P., Tasci B. Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain 1999, 122:2171-2182.
6. Ait Ben Haddou E.H., Imounan F., Regragui W., et al. Neurological manifestations of Behcet's disease: evaluation of 40 patients treated by cyclophosphamide. Rev Neurol (Paris) 2012, 168:344-349.
7. Pipitone N., Olivieri I., Padula A., et al. Infliximab for the treatment of neuro-Behcet's disease: a case series and review of the literature. Arthritis Rheum 2008, 59:285-290.
8. Arida A., Fragiadaki K., Giavri E., Sfikakis P.P. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011, 41:61-70.
9. Marshall S.E. Behcet's disease. Best Pract Res Clin Rheumatol 2004, 18:291-311.
10. Davatchi F., Assaad-Khalil S., Calamia K.T., Crook J.E., Sadeghi-Abdollahi B., Schirmer M., et al. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014, 28:338-347.
11. Kikuchi H., Aramaki K., Hirohata S. Effect of infliximab in progressive neuro-Behçet[U+05F3]s syndrome. J Neurol Sci 2008, 272:99-105.
12. Borhani Haghighi A., Safari A. Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report. Clin Neurol Neurosurg 2008, 110:315-316.
13. Madanat W.Y., Madanat A.Y. Worsening of osteomalacia in a patient successfully treated for neuro-Behçet's disease with infliximab. Clin Exp Rheumatol 2008, 26:S128-S129.
14. Borhani Haghighi A., Safari A., Nazarinia M.A., Habibagahi Z., Shenavandeh S. Infliximab for patients with neuro-Behcet[U+05F3]s disease: case series and literature review. Clin Rheumatol 2011, 30:1007-1012.
15. Abalos-Medina G.M., Sánchez-Cano D., Ruiz-Villaverde G., Ruiz-Villaverde R., Quirosa Flores S., Raya Alvarez E. Successful use of infliximab in a patient with neuro-Behçet's disease. Int J Rheum Dis 2009, 12:264-266.
16. Matsui T., Ishida T., Tono T., Yoshida T., Sato S., Hirohata S. An attack of acute neuro-Behçet's disease during the course of chronic progressive neuro-Behçet's disease: report of two cases. Mod Rheumatol 2010, 20:621-626.
17. Al-Araji A., Siva A., Saip S., et al. Treatment of Neuro-Behcet[U+05F3]s disease with infliximab. An international multi-centre case-series of 18 patients. Clin Exp Rheumatol 2010, 28(Suppl. 60):S119.
18. Belzunegui J., López L., Paniagua I., Intxausti J.J., Maíz O. Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease. Clin Exp Rheumatol 2008, 26:S133-S134.
19. Leccese P., D'Angelo S., Angela P., Coniglio G., Olivieri I. Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab. Clin Exp Rheumatol 2010, 28:S102.
20. Alty J.E., Monaghan T.M., Bamford J.M. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNF alpha blockade. Clin Neurol Neurosurg 2007, 109:279-281.
21. Borhani H.A., Ittehadi H., Nikseresht A.R., et al. CSF levels of cytokines in neuro-Behcet[U+05F3]s disease. Clin Neurol Neurosurg 2009, 111:507-510.
22. Akman-Demir G., Tüzün E., Içöz S., et al. Interleukin-6 in neuro-Behcet[U+05F3]s disease: association with disease subsets and long-term outcome. Cytokine 2008, 44:373-376.
23. Heyser C.J., Masliah E., Samimi A., Campbell I.L., Gold L.H. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. Proc Natl Acad Sci U S A 1997, 94:1500-1505.
24. Gruol D.L., Nelson T.E. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 1997, 15:307-339.
25. Serada S., Fujimoto M., Mihara M., et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2008, 105:9041-9046.
26. Shapiro L.S., Farrell J., Borhani H.A. Tocilizumab treatment for neuro-Behcet[U+05F3]s disease, the first report. Clin Neurol Neurosurg 2012, 114:297-298.
27. Urbaniak P., Hasler P., Kretzschmar S. Refractory neuro-Behcet treated by tocilizumab: a case report. Clin Exp Rheumatol 2012, 30:S73-S75.
28. Calvo-Río V., de la Hera D., Beltrán-Catalán E., Blanco R., Hernandez M., Martinez-Costa L., et al. Tocilizumab in uveitis refractory to other biologic drugs: study of 3 cases and a literature review. Clin Exp Rheumatol 2014, [Epub ahead of print].
29. Diamantopoulos A.P., Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behçet's syndrome: report of two cases. Rheumatology 2013, 52:1923-1924.
30. Kalra S., Silman A., Akman-Demir G., Bohlega S., et al. Diagnosis and management of neuro-Behcet[U+05F3]s disease: international consensus recommendations. J Neurol 2013, 261:1662-1676.